The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, is a groundbreaking gene-editing technology that ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

By creating gene editors not found in nature, or optimizing existing editors, AI can improve the accuracy, effectiveness, and accessibility of gene editing.

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Overnight DeepSeek is the role model of the startup ecosystem. It is demonstrating real-time to every business, idea, or ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene Therapeutics’ ALLO-329, an investigational allogenic CAR-T cell therapy.

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...